New policy marks a shift toward standard regulatory approvals as healthcare providers and manufacturers prepare for the next phase
Washington, D.C., 6 July 2026 – The United States Department of Health and Human Services has announced the termination of the COVID 19 Emergency Use Authorization declarations for drugs, biological products, and medical devices. The decision reflects the government’s view that the emergency conditions that existed during the height of the pandemic have changed significantly and that the healthcare system is now better equipped to rely on traditional regulatory processes.
Emergency Use Authorizations, commonly known as EUAs, were introduced in 2020 to provide faster access to medical products during the COVID 19 public health emergency. These authorizations allowed vaccines, treatments, diagnostic tests, and medical devices to reach patients more quickly while the pandemic created urgent healthcare needs. Over the years, they played an important role in supporting hospitals, healthcare professionals, and patients during an unprecedented global crisis.
The latest decision does not bring an immediate end to these authorizations. Instead, the government has established transition periods to help healthcare organizations, manufacturers, distributors, and patients adapt smoothly. The declaration covering drugs and biological products will end after a twelve-month notice period, while the declaration for medical devices will conclude after one hundred eighty days. This phased approach is intended to minimize disruption across the healthcare system.
Health officials explained that the regulatory environment has changed considerably since the early days of the pandemic. Many medical products that were initially available under emergency authorization have since received full approval, clearance, or licensing through standard regulatory pathways. At the same time, reliance on emergency authorized products has steadily declined as healthcare providers have gained access to a broader range of approved medical technologies.
For manufacturers, the transition creates an opportunity to continue moving products through established regulatory approval processes. During the transition period, the Department of Health and Human Services and the Food and Drug Administration will continue working with companies seeking traditional approvals for products that were previously available under emergency authorization.
Healthcare providers and hospitals are also expected to review their inventories, procurement strategies, and clinical protocols to ensure a seamless shift toward fully approved products. Industry experts believe careful planning will help maintain uninterrupted patient care while supporting long-term regulatory stability.
The decision represents another step in the evolution of healthcare after the pandemic. While emergency authorizations were critical during a period of global uncertainty, the transition toward conventional regulatory oversight reflects the increasing availability of approved medical products and the healthcare system’s ability to operate under established standards. As the transition progresses over the coming months, healthcare organizations, manufacturers, and regulators will work together to ensure continued access to safe and effective medical technologies.